Merck Found a Way to Make Keytruda Even Better at Killing Lung Cancer

Calderasib is designed to unstick that switch. But here's where the combination logic gets clever: when you shut down the KRAS signal, dying tumor cells release proteins that the immune system can recognize. Keytruda, which removes the "invisibility cloak" that cancers use to hide from immune cells, is perfectly positioned to capitalize on that moment. One drug exposes the tumor; the other unleashes the immune system to finish the job.

The clinical results suggest this isn't just theoretical synergy. It's showing up in actual patients.

The Competition Is Fierce

Calderasib isn't entering an empty field. Two KRAS G12C inhibitors are already approved for lung cancer: Amgen's sotorasib (Lumakras) and the BMS/Mirati drug adagrasib (Krazati). Both are cleared for second-line use, meaning after other treatments have failed.

But there's a catch with the first-generation drugs. Their benefits tend to be modest and short-lived as monotherapies, with PFS typically under six months. And sotorasib ran into serious toxicity problems when combined with PD-1 inhibitors like Keytruda in early combination studies.

Merck's pitch is that calderasib plays nicer with immunotherapy. In the KANDLELIT-001 trial, grade 3 liver enzyme elevations (the main safety signal) occurred in just 8% of patients on the combination. The overall side effect profile was described as manageable, with low discontinuation rates.

That tolerability advantage could be calderasib's real differentiator. If you can safely combine a KRAS inhibitor with the world's best-selling cancer drug, you potentially leapfrog straight to first-line treatment instead of waiting for patients to fail other therapies first.

The Market Opportunity

KRAS G12C mutations show up in roughly 10-16% of non-squamous lung cancers. In the United States alone, that translates to approximately 25,000 new patients per year. It's not the largest slice of lung cancer, but it's a precisely defined one where targeted therapy can make a dramatic difference.

Currently, these patients receive the same chemo-plus-immunotherapy cocktail as everyone else with advanced lung cancer. There's no approved targeted option in the first-line setting. If Merck's Phase 3 trials succeed, calderasib plus Keytruda would create an entirely new standard of care for this group.

The Road Ahead

Merck has two major Phase 3 trials already running. KANDLELIT-004 is testing calderasib plus Keytruda against Keytruda alone in patients with very high PD-L1 expression (TPS ≥50%), enrolling roughly 600 patients. KANDLELIT-007 takes a broader swing: calderasib plus subcutaneous Keytruda versus chemo plus Keytruda in all KRAS G12C non-squamous lung cancer patients regardless of PD-L1 status, with about 675 patients enrolled.

The first trial could report results in the next couple of years. The second has a primary completion date of December 2029, so this is a long game.

What Wall Street Thinks

Analysts are calling this "directionally positive" but not thesis-changing for Merck's stock. The real Merck debate still revolves around Keytruda's patent cliff (looming around 2028 in major markets) and whether the company can build enough new revenue streams to offset it.

Calderasib fits neatly into that narrative. It's one piece of a broader strategy to extend Keytruda's relevance through novel combinations that carry their own intellectual property. If Phase 3 confirms the Phase 1 signal, calderasib could anchor KRAS G12C patients in Merck's ecosystem for years.

But let's be honest: Phase 1 response rates don't always hold up in larger trials. Breakthrough Therapy designation is a regulatory fast pass, not a guarantee of approval. The next two years will determine whether these early numbers were a mirage or a genuine leap forward.

The Bottom Line

After 40 years of being "undruggable," KRAS is now the target of a crowded race. Merck's entry is late compared to sotorasib and adagrasib, but it might be arriving with the best dance partner in oncology. A 77% response rate in first-line lung cancer, if it holds, would be remarkable by any standard.

The real question isn't whether KRAS inhibitors work. It's whether they work well enough, safely enough, and early enough to change how doctors treat lung cancer from day one. Merck just got a big vote of confidence that the answer might be yes.

Exelixis Built a Backup Plan for Its $2B Drug. It Just Hit a Wall.

Exelixis' next-generation drug zanzalintinib missed a key survival endpoint in colorectal cancer, sending shares down 10-12%. With Cabometyx still driving 90% of revenue, the pressure to prove the successor can carry the franchise just got a lot more intense.